BioSpace News Archive

Deals

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares - June 25, 2021

Theravance Biopharma, Inc., a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced the pricing of its underwritten public offering of 6,700,000 ordinary shares at a price to the public of $15.00 per share.

June 24, 2021
·
3 min read
Business

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

Helsinn announces Patrick Johnson, MD, as the 2021 recipient of the Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care.

June 24, 2021
·
4 min read
Starpharma to Webcast Live at Life Sciences Investor Forum June 24th

Starpharma will present a pre-recorded presentation at LifeSciencesInvestorForum.com on June 24 th . DATE: Thursday, June 24 th TIME: 2:30 PM ET

June 24, 2021
·
2 min read
Press Releases

Sequencing Reagents Market Declining Cost of Sequencing Procedures Contributes Significantly to Market Growth

The report highlights the trends prevailing in the market, along with market drivers and deterrents.

June 24, 2021
·
6 min read
Deals

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

Boston Scientific Corporation announced it exercised its option to acquire the remaining shares of Farapulse, Inc.

June 24, 2021
·
6 min read
Business

Waters Corporation Appoints Wei Jiang to Board of Directors

Waters Corporation announced the appointment of Wei Jiang to its Board of Directors, effective July 14, 2021.

June 24, 2021
·
4 min read
Genetown

Huntsman Cancer Institute Begins Treatment with Mevion Compact Proton Therapy System

Mevion Medical Systems announced that the first proton center in the Mountain West, the Senator Orrin G. Hatch Center for Proton Therapy, has opened at Huntsman Cancer Institute at the University of Utah and began treating patients on May 11th with the MEVION S250i Proton Therapy System®.

June 24, 2021
·
4 min read
Business

EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines

EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, announced a strategic research and development collaboration agreement.

June 24, 2021
·
4 min read
Drug Development

VectivBio Receives FDA Orphan Drug Designation for Apraglutide for Acute Graft-Versus-Host DiseasePhase 2 trial expected to begin in the first quarter of 2022

VectivBio Holding AG today announced that the FDA has granted orphan drug designation to apraglutide, a next-generation, long-acting GLP-2 analog being developed for rare gastrointestinal (GI) diseases.

June 24, 2021
·
4 min read
Endo’s Qwo® (collagenase clostridium histolyticum-aaes) Data to Be Presented at Cosmetic Bootcamp 2021

Endo International plc data will be presented during Cosmetic Bootcamp Summer Event 2021.

June 24, 2021
·
7 min read